Tirzepatide: the shortlist

Nearly every metabolic pick sells tirzepatide, so the names here will look familiar. What changes is the order and the price. The full metabolic list counts semaglutide, metformin and other drugs; here each card is priced for tirzepatide, and the order uses each provider's tirzepatide offer.

So a program with a low semaglutide price but a high tirzepatide price moves down, and the reverse moves up. If tirzepatide is the drug you want, this is the list to compare.

Tirzepatide is a weekly injection that switches on two gut-hormone receptors, GIP and GLP-1. Semaglutide works on GLP-1 alone. Eli Lilly sells tirzepatide under two names.

Mounjaro was approved on May 13, 2022 for blood sugar in type 2 diabetes. It now covers children 10 and older, and since August 27, 2026, lowering heart-attack and stroke risk in high-risk adults with type 2 diabetes. Zepbound was approved on November 8, 2023 for long-term weight reduction, and on December 20, 2024 for moderate to severe obstructive sleep apnea in adults with obesity.

The Zepbound label starts at 2.5 mg once a week and allows up to 15 mg once a week. It says not to combine tirzepatide with other tirzepatide products or any GLP-1 drug, and it notes "greater fat mass loss than lean mass loss." Can you build muscle on tirzepatide covers what that means for strength.

SURMOUNT-1 followed 2,539 adults with obesity or overweight and no diabetes for 72 weeks. Weight fell 15.0%, 19.5% and 20.9% across the three doses, against 3.1% on placebo.

In the 72-week SURMOUNT-5 head-to-head obesity trial, tirzepatide took off 20.2% of body weight against 13.7% for semaglutide. Waists shrank 7.2 inches (18.4 cm) against 5.1 inches (13.0 cm).

SURMOUNT-OSA tested it in adults with moderate to severe sleep apnea and obesity. Across two trials, breathing interruptions fell by 25.3 and 29.3 events an hour, against about 5 on placebo. That result is the basis for Zepbound's sleep apnea label.

Stopping matters too. In SURMOUNT-4, people who switched to placebo after 36 weeks regained 14.0% of their weight, while those who stayed on lost another 5.5%. Lilly funded every one of these trials, and none tested a compounded version.

Lilly's own self-pay price climbs with the dose. Zepbound vials and KwikPens cost $299 a month at 2.5 mg, $399 at 5 mg and $449 from 7.5 mg up when you refill within 45 days. A late refill pushes 7.5 mg to $499 and the top doses to $699, and needles are extra.

That's a $150 monthly jump from the starting dose to the higher ones, even refilling on time. Many compounded programs here don't step up at all.

Compounded program headlines vary by dose, supply and plan commitment. A flat-dose claim does not establish that every charge or fee stays flat. Prices are withheld where the selected agreement leaves the recurring total unresolved; that gap should not be filled with an introductory price.

Precision Telemed publishes separate introductory and recurring figures. Other programs describe prepaid medication or annual memberships. Compare the total paid today with the recurring amount, and confirm whether membership renews separately from medication. A year of membership does not prove that the drug supply itself lasts a year.

Strut Health describes treatment-specific fixed 30-day and longer supply offers. That is different from calendar-month billing. Confirm the selected dose and refill total, and use the annualized comparison only after the invoice interval is clear. The review explains the relevant offer and policy limits.

FDA decided on December 19, 2024 that the tirzepatide shortage was over. The grace period for state-licensed pharmacies ended March 5, 2025, and for outsourcing facilities on March 19, 2025. Routine copies of Zepbound and Mounjaro have not been allowed since.

On April 30, 2026, FDA proposed keeping tirzepatide off the list of bulk ingredients outsourcing facilities may use. FDA also counts more than 730 adverse-event reports tied to compounded tirzepatide and warns about fake labels on some products. The tirzepatide explainer tracks each step.

Watch the additives and forms. Prime Doctor RX mixes tirzepatide with B12 or glycine, while FDA’s semaglutide-plus-B12 example illustrates that adding an ingredient does not automatically establish a significant difference. That example should not be presented as a tirzepatide-specific authorization. Goldspan Health, Nova and Strut Health sell tirzepatide under the tongue, and SkinnyRx and Willow sell it as a tablet. No approved tirzepatide comes in any form but an injection.

A trial average is not a target that every subscriber should reach. SURMOUNT-1 studied adults without diabetes, while Mounjaro has a diabetes label with a different clinical purpose. A prescriber needs the reason for treatment, relevant conditions and other medicines before choosing between those pathways. A shared ingredient does not make their indications interchangeable.

Maintenance needs its own conversation. SURMOUNT-4 first enrolled people in an open-label treatment period, then randomized those who completed it. The reported 14.0% regain starts from the lower weight at randomization, rather than the original enrollment weight. It does not mean everyone regained all earlier weight loss, and it cannot predict one person's course after stopping.

Ask how the clinic handles a pause, a supply interruption or a treatment change. Those situations should prompt a clinical plan rather than an automatic purchase of a larger prepaid supply. Also distinguish a dose-change request from cancellation: ending an account does not necessarily cancel a prescription already sent for preparation.

The Zepbound label flags severe stomach reactions, dehydration-related kidney injury, gallbladder problems and pancreatitis. Other diabetes medicines can change low-blood-sugar risk. Tell the clinician about the whole medication list, and ask who reviews new symptoms between refills. A coaching message is different from access to the prescribing team.

Oral contraceptive reliability and planned anesthesia are also specific questions for the prescriber. Tirzepatide affects stomach emptying, so the label includes precautions involving oral contraceptives and reports of aspiration during anesthesia or deep sedation. Ask the clinician and surgical team for an individual plan; a purchasing guide cannot supply it.

For a vial offer, establish who will explain the prescription label and resolve a mismatch between the supplied concentration and the instructions. For a branded device, confirm exactly which presentation is being dispensed. Neither a low advertised monthly equivalent nor a pharmacy name answers those practical safety questions.

Vial or pen? A vial means measuring each dose. Ask exactly how that's done and who checks it, since FDA has reports of dosing errors with compounded GLP-1s.

What's the price at each dose? Ask for the full ladder, not the starting figure.

Is anything added? B12, glycine or another ingredient changes what you're buying.

Brand or compounded? If it's Zepbound, ask what the program charges on top of Lilly's price.

What happens if I stop? Ask how the program handles stepping down. Weighing the two main GLP-1s? Read what semaglutide is, or go back to the full metabolic list.